Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving Average of $1.69

Shares of Compugen Ltd. (NASDAQ:CGEN) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.69 and traded as high as $1.96. Compugen shares last traded at $1.89, with a volume of 202,009 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Compugen from a “hold” rating to a “buy” rating in a report on Wednesday, March 6th.

Compugen Price Performance

The stock has a market capitalization of $163.71 million, a price-to-earnings ratio of -8.59 and a beta of 2.64. The firm has a fifty day moving average of $2.45 and a 200 day moving average of $1.69.

Compugen (NASDAQ:CGEN) last posted its earnings results on Tuesday, March 5th. The biotechnology company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.10 by $0.01. The company had revenue of $33.46 million for the quarter, compared to analyst estimates of $60.00 million. Research analysts predict that Compugen Ltd. will post 0.02 EPS for the current year.

Institutional Trading of Compugen

Several institutional investors have recently bought and sold shares of CGEN. Kingsview Wealth Management LLC acquired a new stake in Compugen in the third quarter valued at approximately $78,000. Tocqueville Asset Management L.P. acquired a new stake in Compugen in the third quarter valued at approximately $71,000. Finally, Silverarc Capital Management LLC grew its holdings in Compugen by 6.1% in the third quarter. Silverarc Capital Management LLC now owns 350,188 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 20,000 shares during the period. 12.22% of the stock is owned by institutional investors and hedge funds.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.